Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the eight analysts that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year target price among brokerages […]
More Stories
US Embassy Warns Americans to Reconsider Travel to Saudi Arabia Amid Houthi Strikes
By Jack Phillips The U.S. Embassy in Saudi Arabia’s capital on Tuesday issued renewed warnings about traveling to the country...
Pope Leo XIV Diagnosed With Cancer as Doctors Remove Part of His Lung
By Jill McLaughlin Pope Leo XIV was diagnosed with lung cancer following surgery to remove a section of his lung...
Third-Quarter Earnings Start This Week: Prepare for More Positive Surprises
By Louis Navellier Later this week, financial stocks will launch their third-quarter earnings season, and I expect most of the...
10 Most Anticipated Horror Games Coming Soon in 2026-2027
There is a bunching up of horror titles in the latter part of 2026 and the early months of 2027,...
Supreme Court to Hear Dispute Over Access to DOGE Records
By Matthew Vadum The Supreme Court on Oct. 13 agreed to decide whether a federal judge improperly ordered broad discovery...
Is Imperfect Women Season 2 Renewed?
Apple TV just dropped the most-awaited news for psychological thriller fans. Imperfect Women season 2 is happening. If you watched...